First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine.
Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Medicine (Baltimore). 2021 Jan 29;100(4):e24432. doi: 10.1097/MD.0000000000024432.
Non-alcoholic fatty liver disease (NAFLD) has become a global pandemic, and its incidence is increasing year by year. At present, there are no definite curative drugs for the treatment of NAFLD in modern medicine. Surprisingly, complementary and alternative therapies play an important role and have special advantages. In this study, we will adopt Bayesian network meta-analysis (NMA) to evaluate the efficiency and safety of complementary therapy and alternative therapies for NAFLD.
We will collect randomized controlled trials (RCTs) related to the treatment of NAFLD in PubMed, Cochrane Library, CNKI, and other databases. Two reviewers will screen the literature and extract data in line with the inclusion and exclusion criteria, and then assess the risk of bias according to Cochrane risk of bias assessment tool. The Bayesian NMA will be performed by Stata16.0 and WinBUGS1.4.3.
Our study will compare and rank the efficacy and safety of diverse complementary and alternative therapies for NAFLD.
This study can provide credible evidence for the efficacy and safety of complementary therapies and alternative therapies in the treatment of NAFLD. We expect to assist clinicians and patients to choose the optimal therapeutic regimen.
INPLASY2020120136.
非酒精性脂肪性肝病（NAFLD）已成为全球性流行疾病，其发病率逐年上升。目前，现代医学中尚无明确的治疗 NAFLD 的特效药物。令人惊讶的是，补充和替代疗法发挥着重要作用，具有特殊优势。在本研究中，我们将采用贝叶斯网络荟萃分析（NMA）来评估补充疗法和替代疗法治疗 NAFLD 的疗效和安全性。
我们将检索 PubMed、Cochrane Library、CNKI 等数据库中与治疗 NAFLD 相关的随机对照试验（RCTs）。由 2 位评价者按照纳入与排除标准筛选文献并提取资料，然后依据 Cochrane 偏倚风险评估工具评估偏倚风险。采用 Stata16.0 和 WinBUGS1.4.3 进行贝叶斯 NMA。
我们的研究将比较和排名不同补充和替代疗法治疗 NAFLD 的疗效和安全性。
本研究可为补充和替代疗法治疗 NAFLD 的疗效和安全性提供可靠证据，以期帮助临床医生和患者选择最佳治疗方案。
INPLASY2020120136。
